MYC and metastatic neoplasm: In the metastatic disease setting, TP53 mutations, mut31, PTEN deletion, and MYC amplification were prognostic of poor OS on UVA, while TP53 mutations, PTEN deletion, and MYC amplification were prognostic of poor OS on MVA (Figure 5C, 5D).